SEC Company Response from SUTRO BIOPHARMA, INC. (STRO) (CIK 0001382101) (STRO) — Oct 9, 2019
SUTRO BIOPHARMA, INC. (STRO) (CIK 0001382101)
Date: Oct. 9, 2019 · CIK: 0001382101 · Accession: 0001193125-19-265124
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234101
Letter
SUTRO BIOPHARMA, INC.
310 Utah Avenue,
Suite 150
South San Francisco, CA 94080
October 9, 2019
United States Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Attention:
Office of Life Sciences
Re:
Sutro Biopharma, Inc.
Registration Statement on Form S-3
Filed October 4, 2019
File No. 333-234101
Requested Date: October 11, 2019
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Sutro Biopharma, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Amanda Rose or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
Sincerely,
Sutro Biopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP SUTRO BIOPHARMA, INC. 310 Utah Avenue, Suite 150 South San Francisco, CA 94080 October 9, 2019 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Office of Life Sciences Re: Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed October 4, 2019 File No. 333-234101 Requested Date: October 11, 2019 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Sutro Biopharma, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable. The Registrant hereby authorizes Amanda Rose or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration. Sincerely, Sutro Biopharma, Inc. By: /s/ Edward C. Albini Edward C. Albini Chief Financial Officer cc: William J. Newell, Chief Executive Officer Sutro Biopharma, Inc. Amanda Rose, Esq. Ryan Mitteness, Esq. Fenwick & West LLP